PROGNOSTIC MARKERS OF URINARY BLADDER CANCER

这项研究以两个假设为指导：(1)临界状态的改变 功能蛋白可使癌症表型，并可用于 膀胱癌的生物学分类 进攻性，以及(2)定义这些变化将提供标记 这将是膀胱癌患者个体的预后。 从而改善诊断、治疗和结果。这些在临床上 重要的膀胱标志物将通过 遵循目标。 目的1：评价膀胱癌标志物的临床意义。 功能蛋白在一种蛋白上表现出差异表达 正常和恶性尿路上皮将作为预测指标进行评估 膀胱癌的标志物。实例包括(1)整合素α6β4 它调节细胞与细胞外基质的通讯，(2) 起细胞间黏附作用的整合素α2β1 分子，以及(3)介导细胞间通讯的连接蛋白26 通过形成缝隙连接。 目的2：寻找膀胱癌的新标记物。 将开发新的标记以用于后续的网络整合 协议。例如，与一种病毒结合的单抗DD23 由膀胱癌细胞表达的蛋白，但不表达正常尿路上皮，以及 Mal基因在膀胱癌中的表达下调 与正常尿路上皮相比。 目的3：参与膀胱癌合作网络研究。 这项提议将继续与联合国其他成员进行合作 膀胱癌标志物网络评估膀胱癌预后标志物 膀胱癌。 这些特定的目标将为临床评估膀胱癌的标志物。 利用并确定新的标记，以便通过网络进行有力的评估 协议。通过这一过程，膀胱的临床重要标志物 癌症的诊断和治疗将得到改善。 患有这种疾病的病人。

This research is guided by two hypotheses: (1) alterations in critical functional proteins enable the cancer phenotype and can be used for the classification of bladder cancer into groups of varying biologic aggressiveness, and (2) defining these alterations will provide markers that will be prognostic in individual patients with bladder cancer resulting in improved diagnosis, therapy and outcome. These clinically important bladder markers will be defined and developed through the following aims. Aim 1: Evaluate markers of bladder cancer for clinical relevance. Functional proteins that have demonstrated differential expression on a normal and malignant urothelium will be evaluated for utility as predictive markers of bladder cancer. Examples include (1) the integrin alpha6beta4 which mediates cellular communication with the extracellular matrix, (2) the integrins alpha2beta1 which an function as intercellular adhesion moleculs, and (3) connexin 26 which mediates intercellular communication through the formation of gap junctions. Aim 2: Identify new markers of bladder cancer. New markers will be developed for subsequent incorporation in Network protocols. Examples include the monoclonal antibody DD23 which binds to a protein expressed by bladder cancer cells but not normal urothelium, and the gene MAL which shows decreased expression in bladder cancer in comparison to normal urothelium. Aim 3: Participate in collaborative Network studies of bladder cancer. This proposal will continue ongoing collaboration with other members of the Bladder Cancer Marker Network to critically evaluate prognostic markers in bladder cancer. These specific aims will evaluate markers of bladder cancer for clinical utility and identify new markers for vigorous evaluation through Network protocols. Through this process clinically important markers of bladder cancer will be developed that improve the diagnosis and treatment of patients with this disease.